Axsome Therapeutics Inc. (AXSM) had a good day on the market for Tuesday December 03 as shares jumped 15.12% to close at $45.61. About 3.47 million shares traded hands on 28,085 trades for the day, compared with an average daily volume of n/a shares out of a total float of 34.51 million. After opening the trading day at $45.13, shares of Axsome Therapeutics Inc. stayed within a range of $47.24 to $42.34.
With today’s gains, Axsome Therapeutics Inc. now has a market cap of $1.57 billion. Shares of Axsome Therapeutics Inc. have been trading within a range of $40.52 and $1.94 over the last year, and it had a 50-day SMA of $n/a and a 200-day SMA of $n/a.
Axsome Therapeutics Inc is a United States-based healthcare service provider. As a pre-clinical therapeutics developer, the company attends primarily to central nervous system disorders such as Alzheimer’s. Its product portfolio consists of novel drugs like the AXS-02 (disodium zoledronate tetrahydrate), which is an oral, non-opioid therapeutic for chronic pain and the AXS-05, which is a fixed-dose combination of dextromethorphan and bupropion. The AXS-02 addresses pain in over three conditions, such as complex regional pain syndrome, knee osteoarthritis and chronic low back pain. The AXS-05 on the other hand, treats resistant depression and agitation in patients with Alzheimer’s disease. Both the products have passed the preclinical, Phase 1 and Phase 2 stages of development.
Axsome Therapeutics Inc. is based out of New York, NY and has some 41 employees. Its CEO is Herriot Tabuteau.
